Michael Makris/LinkedIn
Feb 25, 2026, 16:34
Michael Makris: Biomarin Has Decided to Withdraw Roctavian from the Market
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”IMPORTANT.
Biomarin has decided to withdraw Roctavian, the only approved Haemophilia A gene therapy, from the market.
Biomarin announced several months ago that it wanted to sell Roctavian to another company, but since they failed to find a buyer, they made the decision to voluntarily withdraw Roctavian from the market.
The problem was not that this did not work, but rather that there are a lot of other highly effective choices for haemophilia A subjects available.”
Stay updated with Hemostasis Today.
-
May 28, 2026, 17:42Nagendra Sungala: International Clinical Trials Day Validates the Work of Our Hematology Clinical Trials Unit
-
May 28, 2026, 17:41Thomas Pincez: Looking for Great Contributions on Pediatric Hematology
-
May 28, 2026, 17:40Masoabi Sefojane: The Real Cost of a Bleeding Disorder Is More Than Cost Alone
-
May 28, 2026, 17:39Zeyad Kholeif: New Publication on Rapid Plaque Progression Leading to STEMI in a Young Athlete
-
May 28, 2026, 17:39Karina Althaus: Results of the SSC Subcommittee International Survey on HIT
-
May 28, 2026, 16:45Thrilled to Present The ISTH Roberts Award to Donald Arnold – ISTH
-
May 28, 2026, 16:36Connor Webb: IL-6 as a Primer of Platelet Hyperresponsiveness
-
May 28, 2026, 16:19James Farrell: The Power of Linked Electronic Health Records for Understanding Real Patient Journeys
-
May 28, 2026, 16:19Michael Makris: I Hope The Bleeding Disorders Community Supports Kedrion Initiative for FV Deficiency